• Explore /
  • Poster
  • / Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS.

Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS.

Abstract Poster

Authors

null

Jalid Sehouli

NOGGO & Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum and Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Germany

Jalid Sehouli , Felix Hilpert , Sven Mahner , Tanja Neunhoeffer , Philipp Harter , Nikolaus de Gregorio , Claudius Fridrich , Susanne Markmann , Rolf Richter , Jochem Potenberg , Ralf Lorenz , Peter Klare , Marcus Schmidt , Petra Krabisch , Isolde Groell , Gabriele Doering , Antje Belau , Hans-Joachim Lueck , Andreas Du Bois , Radoslav Chekerov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01047891

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5522)

DOI

10.1200/JCO.2016.34.15_suppl.5522

Abstract #

5522

Poster Bd #

345

Abstract Disclosures

Similar Posters

First Author: Christian Kurzeder

First Author: Kathleen N. Moore

First Author: Antonio Gonzalez-Martin

First Author: Martin R. Stockler